[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study].
A randomized and controlled study was undertaken to test whether substitution with factor XIII concentrates influences the clinical course in patients with acute leukaemia and acquired factor XIII deficiency (less than or equal to 60%). A control group of 31 patients was compared with a factor XIII-treated group of 29 patients. Partial factor XIII deficiency was successfully corrected by substitution. On the other hand, there was no statistically significant difference between the two patient groups in the frequency and severity of bleeding complications, transfusion requirements, and the number of remissions. Undesirable side-effects as a result of substitution treatment were not observed.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D005176:Factor XIII / Q000009:adverse effects / Q000627:therapeutic use*; D005177:Factor XIII Deficiency / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D005176:Factor XIII
Blutgerinnungsfaktor-XIII-Substitution bei akuter Leukämie Ergebnisse einer randomisierten und kontrollierten Studie.